INTRODUCTION: Uveal melanoma is a rare intraocular tumor with heterogeneous biological behavior, and additional noninvasive markers that may predict outcome are needed. Diffusion- and perfusion-weighted imaging may prove useful but have previously been limited in their ability to evaluate ocular tumors. Our purpose was to show the feasibility and potential value of a multiparametric (mp-) MRI protocol employing state of the art diffusion- and perfusion-weighted imaging techniques. METHODS: Sixteen patients with uveal melanoma were imaged with mp-MRI. Multishot readout-segmented echoplanar diffusion-weighted imaging, quantitative dynamic contrast-enhanced (DCE) MR perfusion imaging, and anatomic sequences were obtained. Regions of interest (ROIs) were drawn around tumors for calculation of apparent diffusion coefficient (ADC) and perfusion metrics (K (trans) , v e , k ep , and v p ). A generalized linear fit model was used to compare various MRI values with the American Joint Commission on Cancer (AJCC) tumor group and monosomy 3 status with significance set at P < 0.05. RESULTS: mp-MRI was performed successfully in all cases. MRI tumor height (mean [standard deviation]) was 6.5 mm (3.0). ROI volume was 278 mm(3) (222). ADC was 1.07 (0.27) × 10-3 mm(2)/s. DCE metrics were K (trans) 0.085/min (0.063), v e 0.060 (0.052), k ep 1.20/min (0.32), and v p 1.48 % (0.82). Patients with >33 % monosomy 3 had higher K (trans) and higher v e values than those with disomy 3 or ≤33 % monosomy (P < 0.01). There were no significant differences between ADC (P = 0.07), k ep (P = 0.37), and v p with respect to monosomy 3. CONCLUSION: mp-MRI for ocular tumor imaging using multishot EPI DWI and quantitative DCE perfusion is technically feasible. mp-MRI may help predict monosomy 3 in uveal melanoma.
INTRODUCTION:Uveal melanoma is a rare intraocular tumor with heterogeneous biological behavior, and additional noninvasive markers that may predict outcome are needed. Diffusion- and perfusion-weighted imaging may prove useful but have previously been limited in their ability to evaluate ocular tumors. Our purpose was to show the feasibility and potential value of a multiparametric (mp-) MRI protocol employing state of the art diffusion- and perfusion-weighted imaging techniques. METHODS: Sixteen patients with uveal melanoma were imaged with mp-MRI. Multishot readout-segmented echoplanar diffusion-weighted imaging, quantitative dynamic contrast-enhanced (DCE) MR perfusion imaging, and anatomic sequences were obtained. Regions of interest (ROIs) were drawn around tumors for calculation of apparent diffusion coefficient (ADC) and perfusion metrics (K (trans) , v e , k ep , and v p ). A generalized linear fit model was used to compare various MRI values with the American Joint Commission on Cancer (AJCC) tumor group and monosomy 3 status with significance set at P < 0.05. RESULTS: mp-MRI was performed successfully in all cases. MRI tumor height (mean [standard deviation]) was 6.5 mm (3.0). ROI volume was 278 mm(3) (222). ADC was 1.07 (0.27) × 10-3 mm(2)/s. DCE metrics were K (trans) 0.085/min (0.063), v e 0.060 (0.052), k ep 1.20/min (0.32), and v p 1.48 % (0.82). Patients with >33 % monosomy 3 had higher K (trans) and higher v e values than those with disomy 3 or ≤33 % monosomy (P < 0.01). There were no significant differences between ADC (P = 0.07), k ep (P = 0.37), and v p with respect to monosomy 3. CONCLUSION: mp-MRI for ocular tumor imaging using multishot EPI DWI and quantitative DCE perfusion is technically feasible. mp-MRI may help predict monosomy 3 in uveal melanoma.
Authors: P de Graaf; P J W Pouwels; F Rodjan; A C Moll; S M Imhof; D L Knol; E Sanchez; P van der Valk; J A Castelijns Journal: AJNR Am J Neuroradiol Date: 2011-10-27 Impact factor: 3.825
Authors: Pietro Valerio Foti; Renato Farina; Maria Coronella; Stefano Palmucci; Angelo Montana; Alessandra Sigona; Michele Reibaldi; Antonio Longo; Andrea Russo; Teresio Avitabile; Rosario Caltabiano; Lidia Puzzo; Marco Ragusa; Cesare Mariotti; Pietro Milone; Giovanni Carlo Ettorre Journal: Radiol Med Date: 2015-01-13 Impact factor: 3.469
Authors: Jose S Pulido; Norbert G Campeau; Ernst Klotz; Andrew N Primak; Osama Saba; Kaan Gunduz; Herbert Cantrill; Diva Salomão; Cynthia H McCollough Journal: Clin Ophthalmol Date: 2008-06
Authors: P S Tofts; G Brix; D L Buckley; J L Evelhoch; E Henderson; M V Knopp; H B Larsson; T Y Lee; N A Mayr; G J Parker; R E Port; J Taylor; R M Weisskoff Journal: J Magn Reson Imaging Date: 1999-09 Impact factor: 4.813
Authors: Małgorzata Solnik; Natalia Paduszyńska; Anna M Czarnecka; Kamil J Synoradzki; Yacoub A Yousef; Tomasz Chorągiewicz; Robert Rejdak; Mario Damiano Toro; Sandrine Zweifel; Katarzyna Dyndor; Michał Fiedorowicz Journal: Cancers (Basel) Date: 2022-06-27 Impact factor: 6.575
Authors: Pietro Valerio Foti; Antonio Longo; Michele Reibaldi; Andrea Russo; Giuseppe Privitera; Corrado Spatola; Luigi Raffaele; Vincenzo Salamone; Renato Farina; Stefano Palmucci; Andrea Musumeci; Rosario Caltabiano; Marco Ragusa; Cesare Mariotti; Teresio Avitabile; Pietro Milone; Giovanni Carlo Ettorre Journal: Radiol Med Date: 2016-10-17 Impact factor: 3.469
Authors: Michael C Y Tang; Myriam G Jaarsma-Coes; Teresa A Ferreira; Lorna Zwirs-Grech Fonk; Marina Marinkovic; Gregorius P M Luyten; Jan-Willem M Beenakker Journal: J Magn Reson Imaging Date: 2021-10-15 Impact factor: 5.119
Authors: Kirsten Koolstra; Jan-Willem Maria Beenakker; Peter Koken; Andrew Webb; Peter Börnert Journal: Magn Reson Med Date: 2018-11-13 Impact factor: 4.668
Authors: Teresa A Ferreira; Myriam G Jaarsma-Coes; Marina Marinkovic; Berit Verbist; Robert M Verdijk; Martine J Jager; Gregorius P M Luyten; Jan-Willem M Beenakker Journal: Neuroradiology Date: 2021-10-31 Impact factor: 2.804
Authors: Myriam G Jaarsma-Coes; Teresa A Goncalves Ferreira; Guido R van Haren; Marina Marinkovic; Jan-Willem M Beenakker Journal: Melanoma Res Date: 2019-12 Impact factor: 3.599